Swedish Orphan Biovitrum launches Willfact® in Germany

Goals, mission and background Business Strategy CEO'S STATEMENT History 10 year overview Press releases News Financial Reports Calendar Image gallery Presentations Corporate Governance

Home / ...

4/8/2010

Stockholm, Sweden, Les Ulis, France – April 8 , 2010
Swedish Orphan Biovitrum (STO: BVT) and LFB BIOMEDICAMENTS today announced the launch of Willfact® in Germany, a new product for treatment of the bleeding disorder von Willebrand disease. Swedish Orphan Biovitrum and LFB also announced the prolongation of the current distribution agreement through 2014.

Please read the whole press release here.